SLDB - Solid Biosciences Inc
IEX Last Trade
8.92
-0.110 -1.233%
Share volume: 150,301
Last Updated: Fri 30 Aug 2024 09:59:38 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$9.03
-0.11
-1.22%
Fundamental analysis
10%
Profitability
0%
Dept financing
6%
Liquidity
50%
Performance
10%
Performance
5 Days
-6.59%
1 Month
-2.62%
3 Months
16.88%
6 Months
-5.50%
1 Year
146.01%
2 Year
-9.93%
Key data
Stock price
$8.92
DAY RANGE
N/A - $9.19
52 WEEK RANGE
$1.81 - $15.05
52 WEEK CHANGE
$1.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website:
Employees: 134
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 134
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.
Recent news